Jazz Pharmaceuticals reported strong revenue driven by neuroscience assets and strategic pipeline developments, particularly in oncology. However, declines in oncology sales and inventory dynamics affecting Epidiolex, along with a significant financial loss due to acquisition charges, present challenges. The company remains optimistic about future growth with several upcoming regulatory and commercial milestones.

Company Guidance -

Q3 2025

During Jazz Pharmaceuticals' 2025 Second Quarter Earnings Call, the company provided guidance highlighting several key metrics and future expectations. Jazz reported over $1 billion in total revenue for the quarter, with Xywav sales growing 13% year-over-year, driven by strong net patient additions in both narcolepsy and idiopathic hypersomnia. Epidiolex also showed robust demand, contributing to Jazz's confidence in its blockbuster potential. The company anticipates significant growth opportunities in oncology, with pivotal regulatory milestones approaching, such as the FDA PDUFA target action date for dordaviprone on August 18 and for Zepzelca on October 7. Jazz adjusted its financial guidance, slightly lowering its revenue midpoint but raising the lower end of its adjusted net income (ANI) and earnings per share (EPS) guidance due to strategic reductions in SG&A, R&D, and effective tax rate. The company remains focused on executing its strategy for long-term growth, supported by a diversified portfolio, robust pipeline, and disciplined capital allocation.

Strong Revenue Performance

Jazz Pharmaceuticals generated over $1 billion in total revenue in Q2 2025, with neuroscience assets leading the growth. Xywav grew 13% year-over-year, with robust net patient additions in both narcolepsy and idiopathic hypersomnia.

Strategic Pipeline Developments

Jazz is preparing for the anticipated approval of dordaviprone with an upcoming FDA PDUFA target action date of August 18. This could enhance Jazz's presence in rare oncology.

Oncology Pipeline Advancements

Positive Phase III data for Zepzelca presented at ASCO and the addition of a new Phase II trial for zanidatamab in HER2-positive breast cancer highlight progress in Jazz's R&D pipeline.

Financial Guidance and Cash Flow

Despite a modest reduction in revenue guidance, Jazz has raised the lower end of its ANI and EPS guidance for 2025, supported by reductions in SG&A, R&D, and effective tax rate guidance.

Jazz Pharmaceuticals (JAZZ) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

JAZZ Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	5.96 / -	6.61	―	―	―
Aug 05, 2025	2025 (Q2)	-7.61 / -8.25	5.3	-255.66% (-13.55)
May 06, 2025	2025 (Q1)	4.66 / 1.68	2.68	-37.31% (-1.00)
Feb 25, 2025	2024 (Q4)	5.86 / 6.60	5.02	31.47% (+1.58)
Nov 06, 2024	2024 (Q3)	5.50 / 6.61	4.84	36.57% (+1.77)
Jul 31, 2024	2024 (Q2)	4.92 / 5.30	4.51	17.52% (+0.79)
May 01, 2024	2024 (Q1)	4.18 / 2.68	3.95	-32.15% (-1.27)
Feb 28, 2024	2023 (Q4)	5.18 / 5.02	-0.07	7271.43% (+5.09)
Nov 08, 2023	2023 (Q3)	4.93 / 4.84	5.17	-6.38% (-0.33)
Aug 09, 2023	2023 (Q2)	4.45 / 4.51	4.3	4.88% (+0.21)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

JAZZ Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$113.20	$105.93	-6.42%
May 06, 2025	$111.17	$101.44	-8.75%
Feb 25, 2025	$139.67	$144.17	+3.22%
Nov 06, 2024	$111.55	$119.08	+6.75%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Jazz Pharmaceuticals (JAZZ) report earnings?

Jazz Pharmaceuticals (JAZZ) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Jazz Pharmaceuticals (JAZZ) earnings time?

Jazz Pharmaceuticals (JAZZ) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is JAZZ EPS forecast?

JAZZ EPS forecast for the fiscal quarter 2025 (Q3) is 5.96.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing